Phasing out animal testing in preclinical drug trials in favor of unvalidated alternate methodologies could ultimately backfire and raise safety and effectiveness concerns, says Sara Gerke, the ...
Following its release of a roadmap for phasing out animal testing, on March 18, 2026 FDA released a draft guidance on General Considerations for the Use of New Approach Methodologies in Drug ...
On February 23, 2026, the US Food and Drug Administration (FDA) released draft guidance outlining a new “plausible mechanism framework” that offers sponsors of certain individualized rare disease ...
During a joint workshop on Monday, officials from the US Food and Drug Administration (FDA) and National Institutes of Health (NIH) outlined efforts to reduce animal testing. FDA Commissioner Marty ...
On March 18 th, the FDA published draft guidance on validating new approach methodologies (NAMs), including complex in vitro models (CIVMs). For a field long operating without a clear regulatory ...
After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...
The US Food and Drug Administration (FDA) has published a new report calling for a new drug regulatory decision-making paradigm for risk-benefit assessments, rejecting calls for a quantitative-only ...
Chapel Hill, North Carolina--(Newsfile Corp. - May 11, 2026) - iOrganBio, an innovator in intelligent cell manufacturing that ...
Extended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results